IMI - Innovative Medicines Initiative

IMI is a Joint Technological Initiative (JTI), a public-private partnership involving industry, research community and public authorities to pursue common ambitious research objectives. IMI is a joint undertaking between the EU and the pharmaceutical industry association EFPIA. As the largest JTI, IMI supports collaborative research projects and networks of industrial and academic experts. 

IMI 2 under Horizon 2020

In July 2013, the European Commission released its proposal for the Innovative Medicines Initiative 2 (IMI 2), which will develop next generation vaccines, medicines and treatments, and has to be approved by the European legislator (Parliament and Council).

Horizon 2020 rules will apply to the IMI 2 evaluation process and project management. The total proposed budget is EUR 3.45 billion, with EUR 1.725 billion coming from Horizon 2020 and EUR 1.5 billion contributed by EFPIA (the European Federation of Pharmaceutical Industries and Associations). Other life science industries may contribute additional funding if joining IMI 2 project partners. 

Starting in 2014, IMI 2 will run for 10 years.

The Strategic Research Agenda (SRA), published in March 2014, focuses on delivering "the right prevention and treatment for the right patient at the right time". As a result of an extensive stakeholder consultation process, it will guide IMI 2 projects for the coming years.

Participation in IMI projects

IMI launches a new set of research and/or training projects every year, in order to support prospective, pre-competitive pharmaceutical research and development. Project participants are recruited through open and competitive Calls for research proposals. The selection of the winning proposals is based on independent peer review and concluded by a Grant Agreement and Project Agreement.

Calls 2015

The 2015 call, which opened in July and closes on 13 October (first stage) features the following topics:

  • Patient perspective elicitation on benefits and risks of medicinal products
  • Diabetic kidney disease biomarkers (DKD-BM)
  • Inflammation and AD: modulating microglia function
  • Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment 
  • Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease
  • From ApoE biology to validated Alzheimer’s disease targets  

Further information can be found on the  Call 5 - Stage 1 page.

The following topics are under consideration to be included in calls to be launched in autumn:

  • Joint influenza vaccine effectiveness surveillance
  • Development of quantitative system toxicology (QST) approaches to improve the understanding of the safety of new medicines
  • Establishing impact of RSV (respiratory syncytial virus) infection, resultant disease and public health approach to reducing the consequences
  • Coordination and Support Action (CSA) for the Big Data for Better Outcomes programme
  • Real world outcomes across the AD (Alzheimer’s disease) spectrum (ROADS) to better care
  • Development of an outcomes-focused platform to empower policy makers and clinicians to optimize care for patients with haematologic malignancies

Further information on future topics can be found here.

Open calls

IMI 2 - Call 5: Stage 1 Deadline 13 October 2015

Future topics (6th and 7th IMI2 call) 

For more information

Innovative Medicines Initiative - web presence

The Luxembourg BioHealth Cluster

Joint Technology Initiatives (JTIs)


The IMI2 Strategic Research Agenda 


1.17 MB